Cantor Fitzgerald Begins Coverage on Acrivon Therapeutics (NASDAQ:ACRV)

Investment analysts at Cantor Fitzgerald assumed coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research note issued to investors on Friday,Benzinga reports. The firm set an “overweight” rating on the stock.

A number of other analysts have also commented on the company. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Acrivon Therapeutics in a report on Thursday, November 14th. BMO Capital Markets cut their target price on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Finally, KeyCorp initiated coverage on shares of Acrivon Therapeutics in a report on Friday. They issued an “overweight” rating on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Acrivon Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $23.67.

Acrivon Therapeutics Stock Up 4.8 %

Shares of ACRV stock opened at $6.07 on Friday. Acrivon Therapeutics has a 12-month low of $3.19 and a 12-month high of $11.90. The firm has a fifty day moving average of $6.34 and a 200-day moving average of $7.34. The company has a market capitalization of $189.02 million, a price-to-earnings ratio of -2.25 and a beta of 0.77.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP acquired a new position in shares of Acrivon Therapeutics in the second quarter valued at $58,000. State Street Corp grew its stake in Acrivon Therapeutics by 26.4% in the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after buying an additional 47,233 shares during the last quarter. Barclays PLC lifted its position in Acrivon Therapeutics by 51.2% during the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after acquiring an additional 11,273 shares during the last quarter. Exome Asset Management LLC bought a new stake in shares of Acrivon Therapeutics during the third quarter worth approximately $817,000. Finally, JPMorgan Chase & Co. grew its position in shares of Acrivon Therapeutics by 548.3% in the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after purchasing an additional 28,748 shares during the last quarter. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.